To determine the potential for this sub-class of chiral, amino acid appended SSAs to transition into the clinic, a range of in vitro DMPK studies have been performed. A similar range of studies had previously been undertaken for 1, however, here we select 9 as a representative agent for the four chiral SSAs detailed herein, as this SSA demonstrated high levels of ion transport, antimicrobial and anticancer activity. Kinetic solubility studies conducted in PBS buffer at a pH of 7.4 confirmed the maximum solubility of 9 is 271 µM (Table † ). This indicates that solubility should not become a limiting factor for the translation of this sub-class of SSAs during further optimisation into the clinic. Following this, the metabolic stability of 9 was determined against mouse, rat and human liver microsomes. Microsomes contain membrane bound enzymes, such as cytochrome p450, which contribute to first pass metabolism effects, to which a drug must exhibit some resilience. Within this assay the stability of the intact parent compound is monitored with respect to time, during incubation at 37 °C in the presence and absence of the co-factor NADPH -required for cytochrome p450 activity. From these data, the intrinsic clearance (CLint) of the compound can be calculated. The lower this value, the more stable the compound is to the actions of these membrane bound metabolic enzymes. The results of this assay showed 9 to have a CLint < 7.50 µL/min/g of liver for mouse, rat and human microsomes, considered low by industrial standards (Table † ).